|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 113.4 USD | +0.23% |
|
+6.27% | +3.72% |
| 07-08 | Leerink Initiates Revvity at Outperform With $125 Price Target | MT |
| 06-27 | Barclays Trims Price Target on Revvity to $115 From $116 | MT |
PerkinElmer, Inc. (NYSE:PKI) entered into a definitive agreement to acquire Tulip Diagnostics (P) Ltd. on January 9, 2017. The transaction is expected to close in the first quarter of 2017. 7i Capital Advisors LLP acted as financial advisor for Tulip Diagnostics Private Limited.
Crosstree Capital Partners Inc. acted as financial advisor to Tulip Diagnostics Private Limited.
| 1st Jan change | Capi. | |
|---|---|---|
| +3.72% | 13.96B | |
| +4.57% | 212B | |
| +8.61% | 187B | |
| +26.34% | 155B | |
| +33.90% | 115B | |
| +2.17% | 65.5B | |
| +14.50% | 52.87B | |
| -3.30% | 45.25B | |
| -3.98% | 39.7B | |
| +6.66% | 37.72B |
REVVITY, INC. 
